NCT00141245
Completed
Phase 3
Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
ConditionsSeizure Disorder, Partial
DrugsPregabalin
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Seizure Disorder, Partial
- Sponsor
- Pfizer
- Enrollment
- 325
- Locations
- 1
- Primary Endpoint
- Safety Efficacy
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have met the inclusion criteria for preceding double-blind study
- •Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion Criteria
- •Cannot have absence seizures
Outcomes
Primary Outcomes
Safety Efficacy
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial SeizuresSeizure Disorder, PartialNCT00141388Pfizer455
Completed
Phase 3
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00150293Pfizer337
Completed
Phase 3
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00141336Pfizer750
Completed
Phase 2
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.Epilepsy, PartialNCT00141414Pfizer82
Completed
Phase 3
Pregabalin In Partial Seizures Extension StudySeizuresNCT00143130Pfizer's Upjohn has merged with Mylan to form Viatris Inc.227